Podcasts about cll

Evaluate case-based management strategies for chronic lymphocytic leukemia (CLL) from first line to cellular therapy. Credit available for this activity expires: 6/8/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d?ecd=bdc_podcast_libsyn_mscpedu

Payer & Provider Dynamics: Addressing Non-Medical Switching in Oncology for CLL/SLL On this episode guest host Ryan Haumschild, PharmD, MS, MBA, CPEL, Vice President of Pharmacy at Emory University and Emory Health Plan, Winship Cancer Institute, discusses the real-world impact of non-medical switching in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) with Timothy Mok, Manager of Clinical Utilization Intelligence at Kaiser Permanente and board-certified oncology pharmacist, focusing on the drivers behind switching, the risks of disrupting effective therapy, and how shared decision-making and dose modification can help maintain adherence and improve patient outcomes. Sponsored by Abbvie. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Drs. Wierda and O'Brien discuss new combination treatments for CLL that achieve exceptionally high rates of undetectable disease, especially with triplet regimens. They also show that venetoclax-based retreatment works very well, supporting a move away from chemoimmunotherapy.

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn't mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United's Clinical Trial Support Center, who helps break down treatment options, side effects, and the importance of communication with your care team. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Chronic lymphocytic leukemia (CLL) Clinical Trial Support Center Minimal/measurable residual disease (MRD) Patti Robinson Kaufmann First Connection ® program Online Chat Patient Community Support groups Caregiver support Lessons in Blood Cancer Video: CLL Shared Decision Making in Chronic Leukemias interactive program CLL Society Patient Power Additional Blood Cancer United Support Resources: Information Specialists Financial support Free Nutrition Consultations Free telephone/web patient programs Free booklets Caregiver Workbook Young Adult Resources Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by AbbVie Inc.; BeOne Medicines; and Genentech, A Member of the Roche Group.The post Chronic Lymphocytic Leukemia (CLL): Managing Treatment and Finding Balance first appeared on The Bloodline with Blood Cancer United Podcast.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

Drs. Wierda and O'Brien discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.

Living with a chronic blood cancer can bring uncertainty, questions and a need for support that lasts well beyond diagnosis. In this episode, Nelly shares her experience living with chronic myeloid leukemia (CML), offering an honest look at treatment, side effects and daily life (including raising her three sons.) Joined by hematologist Dr. Lynn Savoie, we explore chronic blood cancers like CML and chronic lymphocytic leukemia (CLL), including how they're diagnoses, treated and managed over time. Visit our website for more information on CLL and CML.Looking for support? Our team is here to help. Contact us today.

In this episode of Treating Together, host Marc Braunstein, MD, PhD, associate professor of medicine at the NYU Perlmutter Cancer Center, sits down with Adam Kittai, MD, associate professor and director of the CLL and Lymphoma programs at NYU Perlmutter Cancer Center, for a deep dive into the rapidly evolving frontline treatment landscape in chronic lymphocytic leukemia (CLL). As chemotherapy continues to give way to targeted and time-limited therapies, clinicians face an increasingly complex array of choices, each influenced by disease biology, patient preferences, and emerging clinical trial data. Key Discussion PointsThe episode focuses on the evolving frontline management of CLL and how clinicians can individualize therapy in an era of expanding options. Highlights include: Patient Evaluation and Diagnosis Considerations: Beyond traditional risk factors such as TP53 mutation and IGHV status, importance is also being placed on patient preference, comorbidities, and treatment goals (eg, time-limited vs continuous therapy) to guide treatment decisions. Therapy Selection and Sequencing Strategy: Dr Kittai offers his view on sequencing decisions in the front line: given the lack of robust comparative data, current evidence supports prioritizing the most appropriate upfront regimen rather than relying on uncertain sequencing strategies across agents. Insights From the AMPLIFY Trial (NCT03836261): With the recent February 2026 FDA approval of acalabrutinib (Calquence) plus venetoclax (Venclexta) in the front line, the discussion highlights progression-free survival (PFS) benefits seen in the AMPLIFY trial and favorable safety of the doublet. The Growing Role of Minimal Residual Disease (MRD): The discussion briefly pivots to the use of MRD testing in the clinic today, including data from trials like GLOW (NCT03462719) and FLAIR (EudraCT: 2013-001944-76), and its potential to guide treatment duration. Emerging Therapeutic Strategies in the Pipeline: The conversation looks to the future of CLL care, including Bruton tyrosine kinase (BTK) degraders, next-generation BCL-2 inhibitors, and novel combinations currently under investigation. Managing Richter's Transformation: Dr Kittai covers evolving combination approaches for this aggressive cancer that aim to target both CLL and lymphoma biology, moving beyond chemoimmunotherapy.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most intriguing advancements and strategic moves shaping the future of drug development and patient care. Regeneron has recently ventured into the radiopharmaceuticals market through a substantial $2.1 billion agreement with Australia's Telix Pharmaceuticals. This move marks a significant diversification from Regeneron's traditional focus, such as obesity treatments, to an area that combines radioactive isotopes with targeting molecules for diagnosing and treating diseases like cancer more effectively. The strategic alliance positions Regeneron as a formidable player in this emerging field, promising to expand its therapeutic portfolio and revenue streams. In oncology innovation, GSK is pushing forward with a bold initiative, conducting Phase 3 trials for antibody-drug conjugates (ADCs) in collaboration with Hansoh Pharmaceutical. This effort underscores GSK's commitment to expanding its oncology pipeline, particularly in targeting unmet medical needs through innovative therapies. Antibody-drug conjugates are designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues and offering a precision approach to cancer treatment. Allogeneic CAR-T therapies are also making waves, with Allogene Therapeutics reporting promising early data from their off-the-shelf CAR-T therapy, cema-cel. This therapy effectively eradicated minimal residual disease in lymphoma patients, highlighting the potential of allogeneic approaches to provide accessible cancer treatments without the logistical complexities of autologous methods. In another significant milestone, Ideaya Biosciences, in collaboration with Servier, achieved success with their eye cancer drug candidate meeting its primary endpoint in a crucial Phase 2/3 trial. This success sets the stage for an accelerated FDA approval filing, offering new hope for patients dealing with this challenging condition. Revolution Medicines has made notable progress in oncology as well, with its highly anticipated RAS inhibitor demonstrating improved survival outcomes in a Phase 3 trial for pancreatic cancer. Extending survival by an average of six months compared to chemotherapy could redefine treatment paradigms for one of the most aggressive cancer types. Not every development has been favorable, however. Replimune faced its second FDA rejection for its melanoma candidate RP1, leading to workforce reductions—a testament to the rigorous nature of regulatory approvals and the challenges companies face when bringing novel therapies to market. Meanwhile, BioNTech and Synox Therapeutics are advancing towards FDA approval for their tumor-targeting therapies. These efforts could intensify competition within the oncology space, challenging established giants like AstraZeneca and Daiichi Sankyo. In pain management, AbbVie has expanded its portfolio through a $745 million deal with Haisco Pharmaceutical Group for two non-opioid pain treatment candidates. This move aligns with growing demand for non-opioid alternatives amid the opioid crisis, reflecting a strategic shift towards safer pain management solutions. Spyre Therapeutics has also reported positive Phase 2 results for its ulcerative colitis drug, setting it up as a potential competitor against Takeda's Entyvio. Success here could enhance therapeutic options for patients struggling with this chronic condition, highlighting continued innovation in gastrointestinal disorders. Eli Lilly's recent success with its BTK inhibitor Jaypirca marks a pivotal moment in chronic lymphocytic leukemia (CLL) treatment strategies. Having demonstrated substantial efficacy in a Phase 3 clinical trial—the fourth positive readout—Jaypirca establishes itself as an industry first. Its fixed-duratioSupport the show

Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

On this episode Kirollos Hanna, PharmD, Director of Pharmacy at Minnesota Oncology, discusses the rapidly shifting treatment landscape for chronic lymphocytic leukemia (CLL). The discussion covers the transition toward oral fixed-duration frontline regimens, the latest 2026 NCCN guidelines, and the emerging role of MRD testing. They also explore the clinical and economic implications of these therapies, including how the Inflation Reduction Act (IRA) is reshaping Medicare formulary strategies and patient access. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In today's episode Mazyar Shadman, MD, MPH, discussed results from a post hoc indirect comparison that evaluated zanubrutinib (Brukinsa) from phase 3 SEQUOIA trial (NCT03336333) compared with acalabrutinib (Calquence) plus venetoclax (Venclexta) from the phase 3 AMPLIFY trial (NCT03836261) in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Shadman is a professor in the Clinical Research Division, medical director of Cellular Immunotherapy, and the Innovators Network Endowed Chair at Fred Hutchinson Cancer Center in Seattle, Washington.In our exclusive interview, Dr Shadman began with a top-line overview of how the indirect comparison was conducted and the rationale behind it. After discussing the design of the comparison, Dr Shadman then dove into a conversation on the results of the study, in addition to how it will help oncologists and patients alike in the clinic. Finally, Dr Shadman looked to the future of CLL management and underscored what research he would like to see conducted following the comparison and its results.

Drs. O'Brien and Wierda discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing personalized, accessible information to help patients have more meaningful discussions with their healthcare providers, not to replace the clinician's role. Jen explains, "We know that tens of millions of people are using AI tools in general, like ChatGPT, for health questions, including patients with blood cancers like chronic lymphocytic leukemia or CLL, they're all turning to the different AI tools that are out there. And from our perspective, we see this continuous growth of use, we want to make sure that the right healthcare information is getting fed into those AI resources and tools so that patients are getting the most accurate information possible."   Meg elaborates, "Many patients are using these AI tools to make sense of everything from their PET scans to their blood results, to some of the treatment language they receive in their clinician's or doctor's office. And one of the things that I heard recently from a cancer patient who had uploaded his scans and some test results into an AI platform. And he called me incredibly concerned. He was very concerned about his prognosis and the limited treatment options that he believed were available to him." "So when I pressed further, I found out that this AI platform was the only source of information that he had. So I became concerned when I recognized that the information he received was antiquated. So the treatment results and some of the information he was working from in this incredibly anxious and anxiety-provoking moment were 10 years old. And so in this case, antiquated information was as dangerous as inaccurate information. And both of these remain top concerns at the Lymphoma Research Foundation. And I think across our sector, as we see more and more patients using these tools and platforms to help educate them about their disease and their treatment options." #LymphomaResearchFoundation #LRF #BeOneMedicines #LymphomaAwareness #AIinHealthcare #PatientAdvocacy #BloodCancer #HealthcareInnovation #PatientEmpowerment #PrecisionMedicine #CLL #HealthTech #CancerCare lymphoma.org BeOneMedicines.com Listen to the podcast here

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing personalized, accessible information to help patients have more meaningful discussions with their healthcare providers, not to replace the clinician's role. Jen explains, "We know that tens of millions of people are using AI tools in general, like ChatGPT, for health questions, including patients with blood cancers like chronic lymphocytic leukemia or CLL, they're all turning to the different AI tools that are out there. And from our perspective, we see this continuous growth of use, we want to make sure that the right healthcare information is getting fed into those AI resources and tools so that patients are getting the most accurate information possible."   Meg elaborates, "Many patients are using these AI tools to make sense of everything from their PET scans to their blood results, to some of the treatment language they receive in their clinician's or doctor's office. And one of the things that I heard recently from a cancer patient who had uploaded his scans and some test results into an AI platform. And he called me incredibly concerned. He was very concerned about his prognosis and the limited treatment options that he believed were available to him." "So when I pressed further, I found out that this AI platform was the only source of information that he had. So I became concerned when I recognized that the information he received was antiquated. So the treatment results and some of the information he was working from in this incredibly anxious and anxiety-provoking moment were 10 years old. And so in this case, antiquated information was as dangerous as inaccurate information. And both of these remain top concerns at the Lymphoma Research Foundation. And I think across our sector, as we see more and more patients using these tools and platforms to help educate them about their disease and their treatment options." #LymphomaResearchFoundation #LRF #BeOneMedicines #LymphomaAwareness #AIinHealthcare #PatientAdvocacy #BloodCancer #HealthcareInnovation #PatientEmpowerment #PrecisionMedicine #CLL #HealthTech #CancerCare lymphoma.org BeOneMedicines.com Download the transcript here

Helen talsk to Dr Renata Walewska about CLL management

During a visit to Columbia University Irving Cancer Research Center, experts across hematologic oncology shared their perspectives on key trends and developments in their respective fields. These conversations explored novel therapeutic approaches and translational research that may advance the paradigm across different leukemia, multiple myeloma, and lymphoma populations.First, Nicole Lamanna, MD, an associate clinical professor of medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division at Irving Medical Center, discussed relevant advancements in the management of chronic lymphocytic leukemia (CLL). She described how the FDA approval of fixed-duration acalabrutinib (Calquence) plus venetoclax (Venclexta) may affirm a shift away from standard chemoimmunotherapy in the field. Her discussion also emphasized evaluating the adverse effects and benefit/risk profiles of drug classes such as BTK inhibitors and BCL-2 inhibitors during the treatment decision-making process.Next, Rajshekhar Chakraborty, MD, an assistant professor of medicine in the Division of Hematology/Oncology at Irving Medical Center, touched upon critical themes related to the use of bispecific antibodies for patients with multiple myeloma and other plasma cell disorders. Educating providers on the utility of bispecific antibodies in earlier treatment settings, he noted, is one of the important challenges that the field must address to expand usage of these therapies in community practices. He also highlighted findings from the phase 3 MajesTEC-3 trial (NCT05083169) and how they support the clinical utility of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory disease.Finally, Hua-Jay “Jeff” Cherng, MD, an assistant professor of medicine in the Lymphoma Program in the Division of Hematology and Oncology at Irving Medical Center, detailed translational work that may shape clinical practice in the lymphoma space. He spoke about research aiming to move markers like ctDNA and minimal residual disease from “the bench to the bedside” as part of clinical decision-making for patients with diffuse large B-cell lymphoma (DLBCL). Other future focuses, Cherng said, include leveraging molecular genotyping to improve outcomes for higher-risk subgroups or even replacing chemotherapy with less toxic targeted agents.References CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting. News release. AstraZeneca. February 20, 2026. Accessed March 11, 2026. https://tinyurl.com/38zbx96s Mateos MV, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): results of MajesTEC-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6

Featuring an interview with Prof Constantine Tam, including the following topics: Evolving first-line treatment paradigm for patients with previously untreated chronic lymphocytic leukemia (CLL) (0:00) Considerations for the administration of first-line venetoclax-based regimens (3:24) Mechanism of action of sonrotoclax and observed early-phase efficacy in combination with zanubrutinib; minimal residual disease as a potential clinical trial endpoint (10:01) Continuous versus fixed-duration first-line treatment approaches for previously untreated CLL (14:38) Selecting between up-front acalabrutinib- and zanubrutinib-based time-limited therapy options (19:07) Up-front treatment selection for patients with del(17p) CLL (24:01) Stopping and restarting acalabrutinib for frail patients with previously untreated CLL (26:43) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (30:20) Lisocabtagene maraleucel as treatment for patients with double-refractory CLL (37:00) Perspectives on future roles of novel therapies and treatment strategies (43:11) CME information and select publications

In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including: How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily pretreated patients Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Matthew S. Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research, Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Nelson Hamerschlak, MD, PhD Head of the Department of Hematology, BMT and Clinical Cell Therapy Einstein Hospital Israelita Sao Paulo, Brazil Stephen Stilgenbauer, MD Medical Director, Comprehensive Cancer Center Ulm (CCCU) Head, Early Clinical Trials Unit (ECTU) Head, Division of CLL Department of Internal Medicine III Comprehensive Cancer Center Ulm (CCCU) University of Medical Center Ulm Ulm, Germany Link to the full program: https://bit.ly/4rsZlqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring a slide presentation and related discussion from Prof Constantine Tam, including the following topics: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL): Results from the randomized CLL17 trial (0:00) Six-year follow-up data from the Phase III SEQUOIA trial of zanubrutinib for patients with treatment-naïve CLL and those with del(17p) CLL not randomly assigned (4:59) Primary endpoint analysis of the randomized STAIR trial of time-limited acalabrutinib monotherapy for frail patients with previously untreated CLL (7:25) Safety analyses of acalabrutinib/venetoclax (AV) or AV in combination with obinutuzumab for previously untreated CLL (10:50) Three-year results with zanubrutinib combined with venetoclax in arm D of the Phase III SEQUOIA trial for treatment-naïve CLL (17:15) Early-phase data with sonrotoclax combinations as front-line treatment of CLL (19:12) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (23:27) Long-term extension (LTE1) results from the Phase III ALPINE trial of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL or small lymphocytic lymphoma (R/R CLL/SLL) (28:53) Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with R/R CLL/SLL from the ongoing phase 1 CaDAnCe-101 study (30:35) Real-world outcomes of lisocabtagene maraleucel in CLL (33:04) CME information and select publications

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/ Dr. John Byrd discusses current and emerging strategies for managing double-class-refractory chronic lymphocytic leukemia (CLL) in community settings. He emphasizes the importance of distinguishing resistance from intolerance to BTK inhibitors through clinical history and molecular testing. Data from the BRUIN trial support the use of pirtobrutinib in select patients, while newer agents, including BTK degraders and bispecific antibodies, offer promising potential. Collaboration with CLL specialists is encouraged to guide therapy sequencing and access advanced treatments such as CAR T-cell therapy.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/ This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, toxicities, IGHV status, and TP53 aberrations. They examine recent and emerging data from trials including CLL17, AMPLIFY, and BRUIN CLL-313, as well as novel agents. The conversation underscores the importance of personalized therapy selection in frontline CLL care.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/ This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. Dr. Jennifer Brown discusses how distinguishing between resistance and intolerance to BTK and BCL2 inhibitors informs second-line treatment decisions. The conversation highlights the role of measurable residual disease (MRD) in guiding therapy duration, biomarker reassessment, and shared decision-making based on patient preferences and clinical risk factors.=

In deze podcast, mede mogelijk gemaakt door AstraZeneca en BeOne Medicines, spreekt wetenschapsjournalist Judith Cohen met prof. dr. Stephan Stilgenbauer (Universiteit Ulm, Duitsland) over de huidige eerstelijnsbehandelopties voor patiënten met CLL. Aan bod komen de belangrijkste punten van de meest recente richtlijnupdates en zijn ervaring met de behandeling van CLL-patiënten.Disclosures Prof. dr. Stephan Stilgenbauer: AbbVie, Amgen, AstraZeneca, BeOne Medicines, BMS, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson&Johnson, Lilly, Novartis, Sunesis.

In de podcastserie Proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze speciale aflevering spreekt zij met dr. Paul Hengeveld over zijn proefschrift, getiteld: ‘Molecular risk stratification in chronic lymphocytic leukemia'. Paul vertelt hoe moleculaire risicostratificatie kan helpen in voorspellen van de prognose van patiënten met chronische lymfatische leukemie (CLL) en filosofeert over de toekomst van MRD (measurable residual disease) bij CLL. Paul heeft 27 maart 2024 zijn proefschrift succesvol verdedigd aan de Erasmus Universiteit bij prof. dr. Ton Langerak en co-promotoren dr. Mark-David Levin en dr. Peter Westerweel. Hij kreeg dit jaar tijdens de hematologiedagen het Jaap Steenbergen Stipendium voor het beste hematologieproefschrift van 2024.Referenties Inspiratietip: Belgische televisieserie - Met gevoel voor tumor Prognose CLL – THEMIS2 MRD CLL10 Sequentiële MRD HOVON-139 FLAIR-studie

CLL #1446 (feat. Linkin Park) 04/15/2001 – Sunday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) patches This episode is now 100% complete and newly remastered, Linkin Park are making their 2nd appearance on CLL, one of the fastest rebookings in the show’s history. The band once again prove to be solid guests. The missing 10 minutes have been restored. From Wiki: Hybrid Theory is the debut studio album by American rock band Linkin Park, released on October 24, 2000, through Warner Bros. Records. Recorded at NRG Recordings in North Hollywood, California, and produced by Don Gilmore, the album’s lyrical themes deal with problems lead vocalist Chester Bennington experienced Read More →

CLL #1447 (feat. Alien Ant Farm) 04/16/2001 – Monday Night Show Source – Bryan M. Stream Recording (2001) This episode is now 100% complete with the missing 10 minutes restored, Alien Ant Farm are making their first of two appearances on CLL, they return to the show for their final appearance in October of 2001. They wouldn’t be on air again with Adam until 2006 when they guested on the Adam Carolla Show on KLSX and also crushed it, This is a sleeper classic episode and the band prove to be solid guests. From Wiki: Alien Ant Farm is an American rock band that formed in Riverside, California, United States, in 1996. They have released five studio albums, and have sold over 5 million units Read More →

CLL #1445 (feat. Guttermouth) 04/12/2001 – Thursday Night Show Source – Unknown Stream Recording (2001) with Debbi and Chris Tape (2020) patches This episode is now 100% complete and newly remastered, the missing 10 minutes have been restored. Guttermouth are making their only appearance on CLL. They prove to be a very smart and funny group of guys and blend in well with the show, it’s a shame they never came back on as they have such a fun rapport with the boys. Sleeper Classic episode indeed!   From Wiki: Guttermouth is an American punk rock band formed in 1988 in Huntington Beach, California and currently recording for Rude Records/Bird Attack Records. They have released nine full-length studio albums and two live Read More →

CLL #1444 (feat. The Love Between The Two Hosts) 04/11/2001 – Wednesday Night Show Source – Lost Tape (2020) with Unknown Stream Recording (2001) patches This episode is now 100% complete and newly remastered, this proves to be one of the biggest gas nights for Dr. Drew in the show’s history. Drew is ready to rumble and he lets Adam have it for the entire episode. Drew gets his ass based revenge! The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

CLL #1443 (feat. Ann Danielewski (Poe) and Mark Z. Danielewski) 04/10/2001 – Tuesday Night Show Source – Lost Tape (2020) with Unknown Stream Recording (2001) patches This episode is now 100% complete and newly remastered, the missing 13 minutes have been restored. Poe is making her final appearance on CLL, her brother Mark is making his only appearance. Poe is one of the greatest guests in LL history, it’s too bad she didn’t continue to appear on the show.  From Wiki: Poe (born Anne Decatur Danielewski) is an American singer, songwriter, and record producer.[2][3][4][5][6] Poe’s musical style is a blend of rock, jazz, electronica, folk, and hip hop elements combined with intimate lyrical compositions.

CLL #1442 (feat. Esai Morales) 04/09/2001 – Monday Night Show Source – Lost Tape (2020) with Unknown Stream Recording (2001) patches This episode is now 100% complete and newly remastered, Esai is making his first of two appearances during the Adam era after having appeared on MTV’s LoveLine a couple of seasons prior. Esai attempts to float the “science” from SPIN magazine regarding HIV/AIDS and despite the boys not engaging it would be referenced for years to come.   From Wiki: Esai Manuel Morales Jr. (born October 1, 1962) is an American actor. He played Bob Morales in the 1987 biopic La Bamba. He also appeared in the PBS drama American Family and in the 

CLL #1441 (feat. Nancy Sasaki and Jenny Biondi) 04/08/2001 – Sunday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) patches This episode is now 100% complete and newly remastered, both guests are making their only appearances on the show. The episode is themed around the morning after pill and the debate that still rages regarding it 19 years later. From Wiki: Emergency contraception (EC) are birth control measures that may be used after sexual intercourse to prevent pregnancy. Emergency contraception has not been shown to affect the rates of abortion within a country.[1] There are different forms of EC. Emergency contraceptive pills (ECPs)—sometimes simply referred to as emergency contraceptives (ECs) or the morning-after pill—are medications intended to disrupt or delay 

CLL #1440 (feat. The Love Between The Two Hosts) 04/05/2001 – Thursday Night Show Source – Unknown Stream Recording (2001) This episode features Adam and Drew creating what sounds a lot like Adam’s show ‘Catch a Contractor’ 13 years before it existed. Drew was asleep before the show started after a long day of work, Adam is generally disinterested despite the solid and insane calls.  The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

CLL #1439 (feat. Bryan Herta) 04/04/2001 – Wednesday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) patches This episode is now 100% complete and newly remastered, Bryan is making his 2nd of 3 appearances during the Adam era, he returns to the show in 2004. This proves to be a very fun episode bordering on a sleeper classic. From Wiki: Bryan John Herta (born May 23, 1970, in Warren, Michigan) is an American race car driver. He currently runs his own team, Bryan Herta Autosport in the NTT IndyCar Series. His team won the 2011 Indianapolis 500 with driver Dan Wheldon and the 2016 Indianapolis 500 with driver Alexander Read More →

CLL #1438 (feat. David Alan Grier) 04/03/2001 – Tuesday Night Show Source – Unknown Stream Recording (2001) DAG is returning to the show for his 6th appearance, there were no superior audio sources to pair with the existing fan recording.    From Wiki: David Alan Grier (born June 30, 1956)[1] is an American actor and comedian. He is best known for his work on the sketch comedy television show In Living Color. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

CLL #1436 (feat. Emanuel Sferios and Dr. Charles Grob) 04/01/2001 – Sunday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. It proved to be a very controversial episode at the time and still gets lots of attention for the “education” attempt from the guest in response to Adam using the term “victim.” Emanuel is making his only appearance on the show and Dr. Grob joins them over the phone, the episode is themed around ecstasy and the Dance Safe program. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his Read More →

CLL #1437 (feat. Andy Dick) 04/02/2001 – Monday Night Show Source – Lost Tape (2020) with an Unknown Stream Recording (2001) Patch This episode is now remastered and 100% complete. Huge audio upgrade, Andy is newly sober and returns to the show for perhaps his funniest appearance. Many fans who didn’t like him on past episodes became fans after hearing this episode. From Wiki: Andrew Roane Dick (born Andrew Thomlinson, December 21, 1965)[2] is an American comedian, actor, musician, and television and film producer. Best known as a comic, he is also known for his eccentric behavior, drug addiction, and sexual misconduct allegations and arrests.[3][4] His first regular television role was on the short-lived but influential Ben Stiller Show. In the mid-1990s, he had Read More →

CLL #1435 (feat. The Love Between The Two Hosts) 03/29/2001 – Thursday Night Show Source – Lost Tape (2020) with Debbi and Chris Tape (2020) Patches This episode is now remastered and 100% complete. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

CLL #1434 (feat. The Mighty Mighty Bosstones) 03/28/2001 – Wednesday Night Show Source – Debbi and Chris Tape (2020) with Unknown stream recording (2001) Patches This episode is now remastered and 100% complete. The audio is way better! From Wiki: The Mighty Mighty Bosstones (informally referred to as The Bosstones) is an American ska punk band from Boston, Massachusetts, formed in 1983.[1][2][3] Since the band’s inception, lead vocalist Dicky Barrett, bassist Joe Gittleman, tenor saxophonist Tim “Johnny Vegas” Burton and dancer (“Bosstone”) Ben Carr have remained constant members. The line-up also includes drummer Joe Sirois, saxophonist Leon Silva, guitarist Lawrence Katz and trombonist Chris Rhodes. The Bosstones are often credited as one of Read More →

CLL #1433 (feat. Shannon Roghair and Andy Lukei) 03/27/2001 – Tuesday Night Show Source – Lost Tape (2020) with Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. The audio is amazing!  From Wiki: Temptation Island is an American reality television program broadcast on Fox and USA Network in which several couples agree to live with a group of singles of the opposite sex, in order to test the strength of their relationships. It’s based on the Dutch TV-program Blind Vertrouwen (translated as Blind Faith) created by Endemol and has been adapted by different countries. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Read More →

CLL #1432 (feat. Bill Maher) 03/26/2001 – Monday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. Bill is making his only appearance on CLL and doesn’t stay for the full show. From Wiki: William Maher (/mɑːr/; born January 20, 1956)[2] is an American comedian, political commentator, and television host. He is known for the HBO political talk show Real Time with Bill Maher (2003–present) and the similar late-night show called Politically Incorrect (1993–2002), originally on Comedy Central and later on ABC. Maher is known for his political satire[3] and sociopolitical commentary. He targets many topics including Read More →

CLL #1431 (feat. Jaime Pressly) 03/25/2001 – Sunday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. Jamie is making her first known appearance on the show, though it’s possible she previously appeared while promoting the movie ‘Ringmaster’ in 1998, she did appear on the MTV show. She was scheduled to appear on CLL #1347 but cancelled due to Adam calling her nuts on air. This proves to be a solid episode and Jamie is very involved guest. From Wiki: Jaime Elizabeth Pressly (born July 30, 1977)[1][2] is an American actress and model. She is best known for playing Joy Turner on the NBC sitcom My Name Is Earl, Read More →

CLL #1430 (feat. New Found Glory) 03/22/2001 – Thursday Night Show Source – Lost Tape (2020) with Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. The audio is amazing! Dr. Drew has an insane Brandon Lee joke, the band prove to be fun and super involved guests. Don’t sleep on New Found Glory this is considered one of the best episodes ever recorded, sleeper classic guests for sure! NFG return to the show 5 more times before Adam’s departure. 6 Timers Club! From Wiki: New Found Glory (formerly A New Found Glory)[1] is an American rock band from Coral Springs, Florida, formed in 1997. After forming in 1997, New Found Glory released their debut studio album 

CLL #1427 (feat. The Love Between The Two Hosts) 03/19/2001 – Monday Night Show Source – Debbi and Chris Tape (2020) with Stream Recording (2001) Patches This episode is now remastered and 100% complete. This episode is dubbed “amputee night” after two calls from listeners with amputated limbs. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

CLL #1428 (feat. The Love Between The Two Hosts) 03/20/2001 – Tuesday Night Show Source – Debbi and Chris Tape (2020) with Stream Recording (2001) Patches This episode is now remastered and 100% complete. Adam tells the Terry M. Street Fight Story, which would ultimately be told again on Adam’s KLSX morning show and feature a call from the bat wielding assailant confirming every detail of the assault. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo